Therapeutic areas

They address over 30 serious, chronic, and rare diseases across a broad spectrum of therapeutic areas.

Neurology

Genetic Diseases

Oncology

Hematology

Rheumatology

Dermatology

Nephrology

Gastroenterology

Cardiology

With nearly three decades of expertise in multiple sclerosis, we maintain an extensive product portfolio for the disease through our partnership with Biogen, a global leader in multiple sclerosis and neuroscience research.

We have similar specialization in the field of hematology-oncology. Presently, we represent medicines for rare types of leukemia and lymphomas, as well as oncology treatments indicated for specific types of skin cancer, lung cancer, cervical cancer, breast cancer, ovarian cancer, gastrointestinal stromal tumors (GIST), and cholangiocarcinoma. Our partnerships in this therapeutic area encompass top biopharmaceutical companies, including: Incyte, Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Kyowa Kirin, PharmaMar and Deciphera Pharmaceuticals, a member of ONO Pharma.

By concentrating our efforts on areas characterized by significant therapeutic challenges and unmet needs, we also represent treatments stemming from groundbreaking research for rare genetic diseases. These include spinal muscular atrophy (SMA), Fabry disease, X-linked hypophosphatemia (XLH), hereditary ATTR amyloidosis, primary hyperoxaluria type 1, and acute hepatic porphyria. Leading companies dedicated to cutting-edge science, such as Biogen, Alnylam Pharmaceuticals, Amicus Therapeutics, and Kyowa Kirin, are among our partners in this field.

Our extensive product portfolio is complemented by immunology therapies, including Incyte's first treatment for vitiligo, as well as advanced biosimilar products for a range of rheumatology, dermatology, and gastrointestinal inflammatory diseases. Additionally, we represent therapies in the field of nephrology through our collaboration with CSL Vifor and Vifor Fresenius Medical Care Renal Pharma.